Maximum stenosis Pearson correlation
0.93 Pearson correlation coefficient
- EndpointAgreement of maximum stenosis measurement with reference
- Population117 adult subjects from four sites
- Tested versionCaRi-Plaque configuration described in K242240
FDA-cleared profile
Caristo Diagnostics Ltd. · CT/CTA · FDA-cleared (510(k))
Authorized purpose: CaRi-Plaque is a web-based post-processing tool for trained operators and healthcare professionals that analyzes previously acquired CCTA DICOM data for coronary plaque characteristics, plaque burden, luminal stenosis, and related vessel measurements.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: CaRi-Plaque is a web-based post-processing tool for trained operators and healthcare professionals that analyzes previously acquired CCTA DICOM data for coronary plaque characteristics, plaque burden, luminal stenosis, and related vessel measurements.
Evidence takeaway. Evidence from the reviewed source record: K242240 FDA evidence is a four-site regulatory validation of CaRi-Plaque measurements from CCTA; no independent paper or trial was promoted in this timeboxed review.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
This field has not been curated yet.
This field has not been curated yet.
0.93 Pearson correlation coefficient
0.985 Pearson correlation coefficient
0.999 Pearson correlation coefficient
0.977 Pearson correlation coefficient
K242240
Manufacturer-submitted FDA evidence; it is not an independent clinical-outcome study.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Price not public here; enter your quote
Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.
Service-level policy context; exact product/version and individual claim eligibility are not established. This is not a product code assignment, universal Medicare coverage determination, fee, or price.
Conditional service-level coverage; product eligibility unconfirmed
Medicare / WPS · United States - WPS J5/J8 jurisdictions · Effective 2026-01-01CMS policy context applies to an eligible CCTA plaque-analysis service in a limited WPS policy scope; it does not assign coverage to K242240 or establish individual claim eligibility.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Previously acquired adult CCTA DICOM data sent through a secure PACS or local hard drive for processing.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-07 · FDA 510(k) K242240: CaRi-Plaque
Source context, not route validation: CCTA data can be transferred through secure PACS or local hard drive and the report can be delivered in DICOM-conformant or PDF form; local PACS/RIS routing, identifiers, report ingestion, and turnaround should be acceptance-tested.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-07 · FDA 510(k) K242240: CaRi-Plaque
Source context, not route validation: The exact FDA packet and Caristo product page describe web-based processing in off-site or cloud data-center infrastructure with secure transfer and de-identification before processing; current hosting region, retention, availability, and service-level terms remain unestablished.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-07 · FDA 510(k) K242240: CaRi-Plaque · CaRi-Plaque coronary plaque analysis
Source context, not route validation: Maximum stenosis; total, calcified, non-calcified, and low-density non-calcified plaque volumes; plaque burden; remodeling index; vessel and lumen profiles; and a DICOM-conformant or PDF report for healthcare-professional review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-07 · FDA 510(k) K242240: CaRi-Plaque
Unresolved route: Maximum stenosis; total, calcified, non-calcified, and low-density non-calcified plaque volumes; plaque burden; remodeling index; vessel and lumen profiles; and a DICOM-conformant or PDF report for healthcare-professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-07 · FDA 510(k) K242240: CaRi-Plaque
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Confirm exact deployed controls, encryption, identity and access management, audit, retention, incident response, hosting region, and data-processing terms.
Buyer acceptance guidance derived from the exact FDA and official product workflow; it is not a claimed vendor monitoring service.
Caristo describes transfer of CCTA data through secure PACS or local hard drive, de-identification before cloud processing, internal operator review, and delivery of DICOM-conformant or PDF reports; validate local transfer, identifiers, turnaround, and report ingestion.
product family · checked 2026-09-07Current CaRi-Plaque family page; confirm exact K242240 release, contract data boundary, and operating terms.
The reviewed exact FDA packet describes off-site regional data-center processing, while the current family page describes de-identification before cloud processing; confirm hosting region, retention, availability, and data-processing terms for deployment.
exact submission · checked 2026-09-07The official CaRi-Plaque page lists maximum stenosis, total/calcified/non-calcified/low-density plaque volumes, plaque burden, and remodeling outputs, allowing buyer acceptance criteria to be tied to the returned report.
product family · checked 2026-09-07Current family report description; exact K242240 output formatting and workflow configuration require confirmation.
Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, payer policy, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public list price or contract unit for the exact K242240 configuration was established in the reviewed official sources.
10 sources - 3 history items
Scope: identity, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, integration, deployment, evidenceMetrics, evidenceStudies
Scope: regulatoryIdentity, modalityContext
Scope: intendedUsers, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: recallDiscovery, nativeSubmissionMatching
Scope: identity, productFamily, clinicalUse, implementationCapabilities, evidenceContext
Scope: postmarketSafety
Scope: reimbursementPolicy
Scope: reimbursementPolicy
Regulatory record
510(k)
Research record
human reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Keya Medical Technology Co., Ltd.
Authorized purpose: Coronary plaque and stenosis quantification from CCTA
Canon Medical Informatics, Inc.
Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.
Circle Cardiovascular Imaging, Inc.
Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.
Careverse Technology Pte. Ltd.
Authorized purpose: Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history